Implantable cardioverter-defibrillator (ICD) efficacy associated to mortality amongst sufferers with coronary heart failure with diminished ejection fraction (HFrEF) is considerably improved by a low baseline frailty burden, based on findings printed in JACC: Coronary heart Failure.
Investigators sought to evaluate the impact of baseline frailty burden on the efficacy of ICD remedy for stopping loss of life amongst sufferers with HFrEF. All-cause mortality was the first consequence. Cardiovascular (CV) loss of life, sudden cardiac loss of life (SCD), and all-cause hospitalization had been secondary outcomes.
They carried out a submit hoc evaluation utilizing participant-level knowledge from 1676 members with HFrEF (imply age, 59±12 years; 23% ladies) from the Sudden Cardiac Loss of life in Coronary heart Failure Trial (SCD-HeFT). SCD-HeFT was a multicenter, randomized managed trial that included members with HF and left ventricular ejection fraction of no larger than 35% and New York Coronary heart Affiliation practical class II or III. Individuals had been randomly assigned in a 1:1:1 ratio to ICD remedy, amiodarone, or placebo. ICD remedy consisted of a shock-only single-lead gadget programmed to detect tachycardia (outlined as 18 or 24 beats at a price of 187 beats/min or greater). Within the submit hoc evaluation, members from the amiodarone remedy arm had been excluded.
The investigators of the submit hoc evaluation used the Rockwood Frailty Index (FI) to estimate baseline frailty, then members had been stratified into excessive vs low frailty burden teams (FI > median vs FI ≤ median, respectively). At baseline, members within the excessive frailty group vs low frailty group tended to be youthful, with a better burden of HF signs, conventional CV danger elements, and worse practical standing.
…frailty modified the impact of ICD remedy on all-cause mortality such that adults with a decrease vs greater burden of frailty appeared to derive larger profit.
Median FI for the excessive frailty group was 0.54 (IQR, 0.47-0.60) and median FI for the low frailty group was 0.30 (IQR, 0.23-0.37). In adjusted multivariable Cox fashions, the investigators discovered the remedy impact of ICD remedy for danger of all-cause mortality was considerably modified by baseline frailty standing (Pinterplay =.047). The remedy impact was important for CV mortality (Pinterplay =.02) however not statistically important for sudden cardiac loss of life (Pinterplay =.11) or all-cause readmission (Pinterplay =.54).
Median follow-up was 3.4 years (IQR, 2.5-4.0 years) and 25.4% of members died throughout follow-up. Individuals with excessive frailty vs low frailty had a considerably greater cumulative incidence of all-cause mortality. Excessive vs low frailty burden was related to a forty five% greater danger of all-cause mortality (HR, 1.45; 95% CI, 1.20-1.76; P <.001) in unadjusted evaluation.
Amongst members with low frailty burden, ICD remedy was related to a decrease danger of all-cause mortality (hazard ratio [HR], 0.56; 95% CI, 0.40-0.78) in contrast with members with excessive frailty burden (HR, 0.86; 95% CI, 0.68-1.09).
Limitations of the evaluation embrace lack of generalizability past sufferers who meet SCD-HeFT enrollment standards and SCD-HeFT was carried out greater than 20 years in the past, due to this fact the evaluation can not account for evolving medical remedy.
“Amongst members with HFrEF enrolled in SCD-HeFT, frailty modified the impact of ICD remedy on all-cause mortality such that adults with a decrease vs greater burden of frailty appeared to derive larger profit,” the research authors wrote.
Disclosure: Some research authors declared affiliations with biotech, pharmaceutical, and/or gadget firms. Please see the unique reference for a full checklist of authors’ disclosures.